Standout Papers

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, co... 2019 2026 2021 2023 269
  1. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial (2019)
    Richard Furie, Eric F. Morand et al. The Lancet Rheumatology

Immediate Impact

7 from Science/Nature 61 standout
Sub-graph 1 of 24

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Interferon- γ and infectious diseases: Lessons and prospects
2024 StandoutScience
2 intermediate papers

Works of Ramesh K. Gupta being referenced

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
2019 Standout

Author Peers

Author Last Decade Papers Cites
Ramesh K. Gupta 245 206 104 298 73 1.3k
Shmuel Tiosano 223 191 181 439 84 1.5k
Louisa Ho 212 217 435 275 52 1.6k
A Shore 127 159 327 425 50 1.5k
Sharon L. Kolasinski 95 111 248 358 41 1.2k
Hiroyasu Ishikawa 105 185 235 137 89 1.5k
Moshe Tishler 104 170 157 559 84 1.7k
Ying Zhang 78 221 251 394 76 1.3k
Chia‐Min Chung 124 191 300 108 68 1.4k
Ayşe Balat 169 193 194 67 97 1.0k
Y. Brault 81 517 134 225 45 1.6k

All Works

Loading papers...

Rankless by CCL
2026